NCT03710889View on ClinicalTrials.gov

Early Effects of Abaloparatide on Tissue-Based Indices of Bone Formation and Resorption

PHASE3CompletedINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

September 20, 2018

Primary Completion Date

July 15, 2020

Study Completion Date

July 15, 2020

Conditions
Osteoporosis, PostmenopausalOsteoporosisOsteoporosis VertebralOsteoporosis RiskOsteoporosis FractureOsteoporosis Localized to SpineOsteoporosis, Age-RelatedOsteoporosis SenileOsteoporosis of Vertebrae
Interventions
DRUG

Abaloparatide

Abaloparatide is a novel, synthetic, 34 amino acid peptide designed to be a potent and selective activator of the PTH/PTH-related protein (PTHrP) type 1 receptor (PTHR1) signaling pathway with 41% homology to PTH\[1-34\] and 76% homology to human PTHrP\[1-34\].

Trial Locations (4)

30501

Center for Advanced Research & Education, Gainesville

48230

Henry Ford Health System, Detroit

80401

Panorama Orthopedics & Spine Center, Golden

02114

Harvard Medical School, Boston

All Listed Sponsors
lead

Radius Health, Inc.

INDUSTRY

NCT03710889 - Early Effects of Abaloparatide on Tissue-Based Indices of Bone Formation and Resorption | Biotech Hunter | Biotech Hunter